Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients M Zaccarelli, V Tozzi, P Lorenzini, MP Trotta, F Forbici, ... Aids 19 (10), 1081-1089, 2005 | 173 | 2005 |
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection V Svicher, V Cento, M Bernassola, M Neumann-Fraune, F Van Hemert, ... Antiviral research 93 (1), 86-93, 2012 | 92 | 2012 |
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure F Ceccherini-Silberstein, F Erba, F Gago, A Bertoli, F Forbici, ... Aids 18 (12), 11-19, 2004 | 90 | 2004 |
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ... Clinical infectious diseases 58 (8), 1156-1164, 2014 | 81 | 2014 |
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors V Svicher, F Ceccherini-Silberstein, F Erba, M Santoro, C Gori, ... Antimicrobial agents and chemotherapy 49 (5), 2015-2025, 2005 | 79 | 2005 |
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations F Ceccherini-Silberstein, F Gago, M Santoro, C Gori, V Svicher, ... Journal of virology 79 (16), 10718-10729, 2005 | 67 | 2005 |
Virologic correlates of adherence to antiretroviral medications and therapeutic failure CF Perno, F Ceccherini-Silberstein, A De Luca, A Cozzi-Lepri, C Gori, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S118-S122, 2002 | 66 | 2002 |
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome V Tozzi, M Zaccarelli, S Bonfigli, P Lorenzini, G Liuzzi, MP Trotta, F Forbici, ... Antiviral therapy 11 (5), 553-560, 2006 | 62 | 2006 |
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes V Svicher, C Gori, M Trignetti, M Visca, V Micheli, M Bernassola, R Salpini, ... Journal of hepatology 50 (3), 461-470, 2009 | 51 | 2009 |
Impact of pre-therapy viral load on virological response to modern first-line HAART MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, M Santoro, ... Antiviral therapy 18 (7), 867-876, 2013 | 48 | 2013 |
Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay A Casabianca, C Gori, C Orlandi, F Forbici, CF Perno, M Magnani Molecular and Cellular Probes 21 (5-6), 368-378, 2007 | 47 | 2007 |
Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon J Fokam, R Salpini, MM Santoro, V Cento, R D’Arrigo, C Gori, CF Perno, ... Archives of virology 156, 1235-1243, 2011 | 46 | 2011 |
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development V Svicher, V Cento, R Salpini, F Mercurio, M Fraune, B Beggel, Y Han, ... Digestive and Liver Disease 43 (12), 975-983, 2011 | 45 | 2011 |
Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme MC Bellocchi, F Forbici, L Palombi, C Gori, E Coelho, V Svicher, ... Journal of medical virology 76 (4), 452-458, 2005 | 45 | 2005 |
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs C Alteri, V Svicher, C Gori, R D'Arrigo, M Ciccozzi, ... BMC Infectious Diseases 9, 1-11, 2009 | 42 | 2009 |
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA M Zaccarelli, MM Santoro, D Armenia, V Borghi, W Gennari, C Gori, ... Journal of Clinical Virology 82, 94-100, 2016 | 40 | 2016 |
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy M Zaccarelli, CF Perno, F Forbici, F Soldani, S Bonfigli, C Gori, MP Trotta, ... Clinical infectious diseases 38 (3), 433-437, 2004 | 38 | 2004 |
Molecular diversity of HIV in Albania M Ciccozzi, C Gori, S Boros, MJ Ruiz-Alvarez, A Harxhi, M Dervishi, ... The Journal of infectious diseases 192 (3), 475-479, 2005 | 36 | 2005 |
Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study MG Bocci, R Maviglia, LM Consalvo, DL Grieco, L Montini, G Mercurio, ... European review for medical and pharmacological sciences 24 (23), 12466-12479, 2020 | 35 | 2020 |
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs G Berno, M Zaccarelli, C Gori, M Tempestilli, A Antinori, CF Perno, ... BMC medical genetics 15, 1-7, 2014 | 32 | 2014 |